Thyrotropin-releasing hormone receptor-FKBP12(F36V) fusion protein (TRHR-FKBP12(F36V))

The TRH receptor FKBPF36V fusion is a synthetic chimeric protein that combines the Thyrotropin-releasing hormone receptor (TRHR), a G protein-coupled receptor, with a mutated version of the FK506-binding protein 12 (FKBP12) featuring a phenylalanine-to-valine substitution at position 36 (Clackson et al., 1998, PNAS). This F36V mutation creates a unique hydrophobic pocket that selectively accommodates synthetic "bump" ligands, such as dTAG-13 or Shield-1, which do not bind to the wild-type FKBP12 protein (Nabet et al., 2018, Nature Chemical Biology). This fusion system is primarily employed as a powerful chemogenetic tool in drug discovery and molecular biology to enable the rapid and reversible control of TRHR protein levels and signaling activity. By utilizing the degradation tag (dTAG) system, researchers can induce the proteasomal degradation of the entire fusion protein within minutes to hours, providing a high-resolution method to study the receptor's physiological roles (Nabet et al., 2018, Nature Chemical Biology). Biologically, the TRHR component of the fusion functions by binding its endogenous ligand, TRH, to activate the Gq/11 signaling pathway, which triggers phospholipase C and increases intracellular calcium levels (UniProt P30810). This pathway is critical for the regulation of the hypothalamic-pituitary-thyroid axis, stimulating the release of thyroid-stimulating hormone (TSH) and prolactin from the anterior pituitary. In a research or therapeutic validation context, the fusion protein is targeted by TRH analogs like taltirelin for receptor activation or by heterobifunctional dTAG ligands for targeted protein degradation. The use of this fusion protein is instrumental in validating TRHR as a therapeutic target for conditions such as central hypothyroidism and certain neurological disorders, while also allowing for the investigation of GPCR scaffolding functions independent of canonical signaling (Nabet et al., 2018, Nature Chemical Biology).

Other names

TRH receptor FKBPF36V fusionTRHR-FKBPF36VTRH receptor-dTAGTRHR-FKBP(F36V) fusionThyrotropin-releasing hormone receptor-FKBP12 variant

The TRH receptor portion acts as a G protein-coupled receptor that activates the Gq/11 pathway upon binding agonists like TRH (UniProt P30810). The FKBP12(F36V) portion acts as a "degradation tag" (dTAG); when a heterobifunctional dTAG ligand (e.g., dTAG-13) is added, it recruits an E3 ubiquitin ligase such as Cereblon (CRBN) to the fusion protein, leading to its polyubiquitination and subsequent degradation by the 26S proteasome (Nabet et al., 2018, Nature Chemical Biology). Alternatively, the fusion can be stabilized by the small molecule Shield-1, which binds the FKBP12(F36V) domain and prevents its inherent instability (Banaszynski et al., 2006, Cell).